Roth Capital Partners appointed Charles “Tony” Butler as a managing director, senior research analyst and head of biotechnology research, and a partner.
Dr. Butler was most recently a senior healthcare analyst and managing director at Guggenheim Securities, where he focused on both biotechnology and biopharma, specifically carving out immune oncology as a driver for the healthcare industry. He also had stints at Lehman Brothers/Barclay’s Capital and Raymond James.
Dr. Butler trained as a post-doctoral fellow in the lab of Dr. Emil Gotschlich at the Rockefeller University, who was responsible for creating the first vaccine for the prevention of meningitis. Dr. Butler’s work at Rockefeller involved developing an understanding of the pathogenesis of certain diseases.
In a statement, Jeff Martin, Roth’s director of research, said Dr. Butler’s strong academic background and extensive experience in covering biotechnology companies would serve Roth’s clients well.
CEO Byron Roth said Dr. Butler’s addition further demonstrates the firm’s commitment to building its presence in the life sciences space. “Tony’s experience in sell-side healthcare research and his knowledge of the industry will enhance our ability to continue to build on our success in assisting both companies and investors in the sector.”
